<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703454</url>
  </required_header>
  <id_info>
    <org_study_id>CLN - 107</org_study_id>
    <nct_id>NCT02703454</nct_id>
  </id_info>
  <brief_title>FIRM Ablation Versus Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation (PAF)</brief_title>
  <acronym>FIRMAP-AF</acronym>
  <official_title>Focal Impulse and Rotor Modulation Ablation Versus Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Electrophysiology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Electrophysiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a prospective, multicenter, single-blind, randomized study to assess
      the safety and effectiveness of FIRM-guided radiofrequency (RF) ablation procedures for the
      treatment of symptomatic PAF. The subjects will be blinded to study treatment for the
      duration of the study period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single-procedure freedom from AF/AT recurrence from 3-12 months post index ablation procedure</measure>
    <time_frame>3 -12 months post study treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from procedure-related serious adverse events</measure>
    <time_frame>Within 1 year post study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>FIRM-only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be treated with FIRM-guided conventional RF ablation without pulmonary vein isolation (PVI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will undergo conventional RF ablation with confirmation of PVI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FIRM-guided RF ablation</intervention_name>
    <arm_group_label>FIRM-only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional RF ablation</intervention_name>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Experiencing at least two (2) documented episodes of paroxysmal atrial fibrillation in
             the last 3 months preceding study entry with clinical indication for AF ablation per
             guidelines. At least one episode should be documented by rhythm strip or ECG.

          -  Indicated for AF ablation according to current EHRA guidelines.

          -  Prescribed with oral anticoagulation therapy, in indicated patients per the latest
             EHRA guidelines.

          -  Willingness and able to remain on anti-coagulation therapy as per the latest EHRA
             guidelines.

          -  Left atrial diameter &lt; 5.5 cm as measured and image ((CT/TEE/TTE/ MRI or ICE)
             documented within previous six months up to pre-procedure.

          -  Sustained AF (&gt;5 min uninterrupted) during the electrophysiology procedure. If the
             subject is not experiencing spontaneous, sustained AF, it may be induced by burst
             pacing (typically from the coronary sinus) with or without isoproterenol infusion in
             conventional clinical fashion.

        Key Exclusion Criteria:

          -  NYHA Class III - IV.

          -  Ejection fraction &lt; 40% (within previous six months).

          -  History of myocardial infarction (MI) within the past three months.

          -  Any concomitant arrhythmia or therapy that could interfere with the interpretation of
             the results from this study.

          -  ASD closure device, LAA closure device, prosthetic mitral or tricuspid valve, or
             permanent pacemaker.

          -  Any previous AF catheter ablation.

          -  History of prior cardioversion for AF lasting &gt; 48 hours.

          -  Continuous AF episode lasting &gt; 7 days immediately prior to the procedure without a
             sinus rhythm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland R. Tilz, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität zu Lübeck</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phillipp Sommer, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Quach</last_name>
    <phone>16506812047</phone>
    <email>andrea.quach@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Tilz, PD Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Roland Tilz, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

